CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Curanex Pharmaceuticals Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$4.92+0.30 (+6.49%)

Close on Oct 19, 2026

Market cap: $139.55M
P/E (TTM): –
Dividend yield: –

Curanex Pharmaceuticals Inc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31
Research & Development	7.83	–	2.99	–	–	–	–
General & Administrative	2.72	2.05	1.25	0.54	0.36	0.35	0.29
Operating Expenses	11	7.28	4.24	1.29	0.44	0.42	0.37
Operating Income	-11	-7.28	-4.24	-1.29	-0.44	-0.42	-0.37
Interest Expense	–	–	0.01	–	–	–	–
Net Income	-10	-7.24	-4.23	-1.30	-0.44	-0.42	-0.36
EPS (Basic)(per share)	-0.38	-0.26	-0.17	–	–	–	–
EPS (Diluted)(per share)	-0.38	-0.26	-0.17	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	28	27	25	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	28	27	25	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -72.1%

Financial strength

Current ratio: 45.95
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2817.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 29.15
Dividend yield: –